- Los Angeles US-CA
For over 20 years, clinical pharmacist Andrew Komesu has held professional positions within hospital and retail settings. He is a BS Pharm graduate of Creighton University, where he obtained specialized training in infectious diseases. Among the areas in which Andrew Komesu gained experience was the implementation of a pharmacoeconomics program. Pharmacoeconomics refers to the study of economic impact of drug therapies or services within a healthcare setting or within a society. In order to determine the therapies or services that provide the best health outcomes for the resources invested, pharmacoeconomics researchers analyze the costs and benefits of these interventions. Findings from these studies help clinicians and policy makers select the most cost-effective treatment options. As a subdivision of outcomes research, pharmacoeconomics strives to state the value of pharmaceuticals in quantifiable terms. The perspective of the pharmacoeconomics study is important, because it influences how value is determined. A study may take one or more perspectives, such as from the point of view of the healthcare provider or the patient. As the consumers of health care, patients will want to know the value of pharmaceuticals with respect to their obligation for copayments and out-of-pocket expenses. On the other hand, the provider will be more interested in comparing the actual costs versus the charged costs for the drug therapy provided. Next, the study focuses on identifying and measuring various cost categories associated with two or more treatment alternatives with respect to a specific population or organization. Ultimately, the study compares the alternatives according to these cost categories and estimates their total economic impact. Finally, pharmacoeconomic studies discuss outcomes, as well as positive and negative consequences of treatment alternatives. A complete model for decision making might incorporate into this section an analysis of economic, clinical, and humanistic outcomes.